WPC June, 2016 - From syngeneic to humanized mouse models: addressing the needs for novel immunotherapies
Oncodesign, Dijon ; INSERM 866, Université de Bourgogne, Dijon ; Center Georges François Leclerc, Dijon
Oncodesign, Dijon ; INSERM 866, Université de Bourgogne, Dijon ; Center Georges François Leclerc, Dijon
Oncodesign, Dijon, (France) Center Georges Francois Leclerc, Dijon (France)
INSERM 866, Université de Bourgogne, Dijon, (France) Center Georges Francois Leclerc, Dijon, (France) Oncodesign, Dijon (France)
Ariana Pharmaceuticals, Paris; 2 Biofortis Merieux Nutrisciences, Saint-Herblain; 3 CTI-BIOTECH, Lyon; 4 Modul-Bio, Marseille; 5 Oncodesign, Dijon ; 6 Oncomedics, Limoges; 7 Ipsen Innovation, Les Ulis; 8 Pierre Fabre Research Institut, St-Julien-en-Genevois; 9 Sanofi, Vitry-sur-Seine; 10 Servier Research Institut, Suresnes; 11 CNRS U5059, Toulouse; 12 Centre Georges François Leclerc, Dijon;13 Toulouse Hospital; 14 Centre Léon Bérard, Lyon; 15 INSERM U938, Paris; 16 INSERM U1033, Lyon; 17 INSERM U1037, Toulouse; 18 INSERM U1052, Lyon; 19 INSERM U1068, Marseille; 20 INSERM U1111, Lyon; 21 Fondation Synergie Lyon Cancer, Lyon; 22 Strasbourg University; 23 Pitié-Salpetrière Hospital, Paris - FRANCE